Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Acquires $12,800.00 in Stock

Nuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) CEO Ron Bentsur acquired 2,000 shares of Nuvectis Pharma stock in a transaction dated Friday, May 10th. The shares were purchased at an average cost of $6.40 per share, with a total value of $12,800.00. Following the completion of the transaction, the chief executive officer now directly owns 3,244,484 shares of the company's stock, valued at $20,764,697.60. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Ron Bentsur also recently made the following trade(s):

• On Monday, March 18th, Ron Bentsur acquired 5,000 shares of Nuvectis Pharma stock. The stock was acquired at an average cost of $10.29 per share, for a total transaction of $51,450.00.

Nuvectis Pharma Stock Down 0.8 %

Shares of NVCT stock traded down $0.05 on Monday, reaching $6.35. The stock had a trading volume of 94,484 shares, compared to its average volume of 99,309. Nuvectis Pharma, Inc. has a 12 month low of $5.92 and a 12 month high of $18.65. The firm has a market capitalization of $116.59 million, a price-to-earnings ratio of -4.50 and a beta of 0.45. The firm's 50-day moving average is $7.93 and its two-hundred day moving average is $8.15.

Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) last released its quarterly earnings results on Tuesday, March 5th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.01). On average, sell-side analysts forecast that Nuvectis Pharma, Inc. will post -1.29 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Nuvectis Pharma

A number of large investors have recently added to or reduced their stakes in the stock. Strs Ohio lifted its holdings in shares of Nuvectis Pharma by 178.6% during the 3rd quarter. Strs Ohio now owns 3,900 shares of the company's stock worth $50,000 after acquiring an additional 2,500 shares during the period. Blue Zone Wealth Advisors LLC acquired a new stake in shares of Nuvectis Pharma in the 1st quarter valued at $118,000. Edmond DE Rothschild Holding S.A. acquired a new stake in shares of Nuvectis Pharma in the 4th quarter valued at $160,000. Baldwin Brothers LLC MA increased its stake in shares of Nuvectis Pharma by 22.0% in the 4th quarter. Baldwin Brothers LLC MA now owns 142,040 shares of the company's stock valued at $1,185,000 after purchasing an additional 25,660 shares during the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of Nuvectis Pharma by 1.5% during the 1st quarter. Vanguard Group Inc. now owns 298,800 shares of the company's stock worth $2,450,000 after buying an additional 4,517 shares in the last quarter. Institutional investors and hedge funds own 96.77% of the company's stock.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a "buy" rating and set a $21.00 target price on shares of Nuvectis Pharma in a report on Wednesday, May 8th.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.